Übersetzung für "Giant cell arteritis" in Deutsch

You can't explain a transudative pleural effusion with Giant Cell Arteritis.

Background: The occipital artery can become inflamed in giant cell arteritis.

I'd say giant cell arteritis.

It's gotta be Giant Cell arteritis.

Giant cell arteritis – also known as temporal arteritis – is a potentially life-threatening autoimmune condition.

Objective: The giant cell arteritis is a disease of the elderly, that frequently leads to blindness.

Therefore, fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in patients with positive family history of aneurysm disease, or in patients diagnosed with pre-existing aortic aneurysm and/or aortic dissection, or in presence of other risk factors or conditions predisposing for aortic aneurysm and dissection (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet's disease, hypertension, known atherosclerosis).

Insights into the mechanisms that cause and drive RA have meant we can also help people who have other autoimmune disease – for example, at Roche we are investigating rare diseases such as systemic sclerosis and giant cell arteritis.

Background: Giant cell arteritis (GCA) is the most common systemic vasculitis in persons aged 50 and above (incidence, 3.5 per 100Â 000 per year).

ESR should be done if patients have visual symptoms, jaw or tongue claudication, temporal artery signs, or other findings suggesting giant cell arteritis.

With erythema nodosum, nodular periarteritis, giant cell arteritis, Takayasu arteritis, Schenlein-Genoch syndrome, vasculitis is characterized by limited - only veins, large arteries, small arteries and capillaries, or any of them, for example limbs or head, are affected.

Giant cell arteritis (GCA) - also known as temporal arteritis (TA) - is a potentially life-threatening autoimmune condition.

Neil Collinson, PhD, Senior Clinical Development Scientist Giant cell arteritis (GCA, temporal arteritis) is an inflammatory disease that affects medium- and large-sized arteries, primarily those supplying the temple, scalp, face and eyes and the aorta and its branches that supply the neck and arms.

The inhibition of IRAK4 enables the prophylaxis and/or treatment of atherosclerosis, type 1 diabetes mellitus, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, psoriasis, vitiligo, giant cell arteritis, chronic inflammatory bowel disorder and viral disorders, for example HIV (human immunodeficiency virus), hepatitis virus (Staschke, et al., The Journal of Immunology, 2009;

Roche today announced positive results from the Phase III study known as GiACTA, which evaluated Actemra®/RoActemra® (tocilizumab) in people with giant cell arteritis (GCA).

In May, Actemra/RoActemra subcutaneous injection was approved by the FDA for the treatment of giant cell arteritis.

In the same month, the largest clinical trial ever conducted in giant cell arteritis (GCA), a serious inflammatory disease of blood vessels, showed positive results.

Patients with a histological proof of giant cell arteritis showed a remarkable side difference of the intraarterial space in respect to ultrasound imaging.

The typical symptoms and findings of giant cell arteritis (GCA) are still too often misinterpreted, and urgently needed treatment is delayed.

Roche today announced positive results from the phase III GiACTA study, which evaluated Actemra®/RoActemra® (tocilizumab) in people with giant cell arteritis (GCA).